- Home
- CTOR vs CTMX Comparison
CTOR vs CTMX Comparison
Compare CTOR & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- CTMX
- Stock Information
- Founded
- CTOR 2021
- CTMX 2008
- Country
- CTOR United States
- CTMX United States
- Employees
- CTOR N/A
- CTMX N/A
- Industry
- CTOR
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- CTOR
- CTMX Health Care
- Exchange
- CTOR NYSE
- CTMX Nasdaq
- Market Cap
- CTOR 63.7M
- CTMX 444.3M
- IPO Year
- CTOR N/A
- CTMX 2015
- Fundamental
- Price
- CTOR $2.87
- CTMX $2.42
- Analyst Decision
- CTOR Buy
- CTMX Strong Buy
- Analyst Count
- CTOR 2
- CTMX 2
- Target Price
- CTOR $6.00
- CTMX $5.00
- AVG Volume (30 Days)
- CTOR 2.7M
- CTMX 2.4M
- Earning Date
- CTOR 08-11-2025
- CTMX 08-07-2025
- Dividend Yield
- CTOR N/A
- CTMX N/A
- EPS Growth
- CTOR N/A
- CTMX 128.27
- EPS
- CTOR N/A
- CTMX 0.49
- Revenue
- CTOR N/A
- CTMX $147,557,000.00
- Revenue This Year
- CTOR N/A
- CTMX N/A
- Revenue Next Year
- CTOR N/A
- CTMX N/A
- P/E Ratio
- CTOR N/A
- CTMX $5.36
- Revenue Growth
- CTOR N/A
- CTMX 23.81
- 52 Week Low
- CTOR $0.55
- CTMX $0.40
- 52 Week High
- CTOR $49.00
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- CTMX 52.71
- Support Level
- CTOR N/A
- CTMX $2.33
- Resistance Level
- CTOR N/A
- CTMX $2.79
- Average True Range (ATR)
- CTOR 0.00
- CTMX 0.18
- MACD
- CTOR 0.00
- CTMX -0.01
- Stochastic Oscillator
- CTOR 0.00
- CTMX 46.38
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.